Peptide Receptor Modulator Research Series – Single, Dual, and Triple Agonist Investigational Compounds.
| Product Specifications | |
|---|---|
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molecular Weight (g/mol) | 4731.33 |
| Amino Acid Count | 39 |
| Amino Acid Sequence | H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(γ-Glu-(AEEA)-C20-diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Purity | ≥99% by HPLC | COA available |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in bacteriostatic water; consult COA for specific solvent recommendations |
| Storage Conditions | Store at -20°C; protect from light and moisture; reconstitute with bacteriostatic water |
For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures.
This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.
Published Literature
| # | Reference | Link |
|---|---|---|
| [01] | Jastreboff A.M., Aronne L.J., Ahmad N.N., et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022;387:205–216. | NEJM PubMed |
| [02] | Garvey W.T., Frias J.P., Jastreboff A.M., et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes: SURMOUNT-2. Lancet. 2023;402(10402):613–626. | PubMed |
| [03] | Wadden T.A., Chao A.M., Machineni S., et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: SURMOUNT-3. Nature Medicine. 2023;29:2909–2918. | PubMed Journal |
| [04] | Aronne L.J., Sattar N., Horn D.B., et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4. JAMA. 2024;331(1):38–48. | PubMed Full Text |
| [05] | Frias J.P., Davies M.J., Rosenstock J., et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021;385:503–515. | PubMed NEJM |
| [06] | Del Prato S., Kahn S.E., Pavo I., et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk: SURPASS-4. Lancet. 2021;398(10313):1811–1824. | PubMed |
| [07] | Malhotra A., Grunstein R.R., Fietze I., et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 2024;391:1193–1205. | PubMed NEJM |
| [08] | Loomba R., Hartman M.L., Lawitz E.J., et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 2024;391:299–310. | PubMed NEJM |
| [09] | Jastreboff A.M., le Roux C.W., Stefanski A., et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 2025;392:958–971. | PubMed NEJM |
| [10] | Aronne L.J., Sattar N., Horn D.B., et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 2025. | PubMed NEJM |
Receptor Binding Profile
| Compound | Primary Receptor Target | Binding / Activity Profile | Reported Potency / Affinity | Functional Effect |
|---|---|---|---|---|
| Retatrutide | GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR) | Triple hormone receptor agonist; binds to and activates GIPR, GLP-1R, and GCGR, with stronger reported activity at GIPR compared with GLP-1R and GCGR | Human receptor EC50 values reported: GIPR: 0.0643 nM; GLP-1R: 0.775 nM; GCGR: 5.79 nM | Activates multi-receptor incretin and glucagon signaling pathways associated with glucose regulation, reduced calorie intake through GIPR/GLP-1R pathways, and increased energy expenditure through GCGR activity in pharmacology studies (sciencedirect.com) |
